Immune checkpoint inhibitors in cervical cancer: Current status and research progress

Cervical cancer is the second most common gynecological malignant tumor endangering the health of women worldwide. Despite advances in the therapeutic strategies available to treat cervical cancer, the long-term prognosis of patients with recurrent and metastatic cervical cancer remains unsatisfacto...

Descripción completa

Detalles Bibliográficos
Autores principales: Xie, Yunkai, Kong, Weimin, Zhao, Xiaoling, Zhang, He, Luo, Dan, Chen, Shuning
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9647018/
https://www.ncbi.nlm.nih.gov/pubmed/36387196
http://dx.doi.org/10.3389/fonc.2022.984896

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9647018/
https://www.ncbi.nlm.nih.gov/pubmed/36387196
http://dx.doi.org/10.3389/fonc.2022.984896

Ejemplares similares